[Psychopharmacotherapy of anxiety disorders in patients with cardio-vascular diseases: the use of aphobazole].
Afobazole was administered to 32 patients, aged 18-60 years, with cardio-vascular diseases and neurotic stress-related psychopathologies and somatoform disorders (ICD-10 F40-F45). The drug was assigned in dosages from 30 to 60 mg daily (mean 50 mg) during 6 weeks, along with basic somatotropic therapy. Twenty-nine patients completed the course. Therapeutic efficacy was assessed by the Hamilton anxiety scale (HAM-A) and a subscale of the Global Clinical Impression scale (CGI). The total number of responders was 21 (70%). The improvement began from the 1st week of the treatment and increased to the 42nd day. At the same time, intensity of mental disorders (phobic, somatisized, anxiety-depressive) gradually decreased up to complete reduction. Afobazole was well-tolerated by patients.
Medvedev
V E
VE
Trosnova
A P
AP
Dobrovol'skiĭ
A V
AV
D000293:Adolescent; D000328:Adult; D001008:Anxiety Disorders / Q000150:complications / Q000188:drug therapy*; D001562:Benzimidazoles / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000150:complications*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use*; D016896:Treatment Outcome
C410924:2-((2-morpholino)ethylthio)-5-ethoxybenzimidazole; D001562:Benzimidazoles; D009025:Morpholines